J P Morgan Chase & Co Downgrades Advanced Accelerator Applications S.A. (AAAP) to Neutral
Advanced Accelerator Applications S.A. (NASDAQ:AAAP) was downgraded by J P Morgan Chase & Co from an “overweight” rating to a “neutral” rating in a research report issued to clients and investors on Monday, Marketbeat reports. They currently have a $82.00 price objective on the stock. J P Morgan Chase & Co’s target price would suggest a potential upside of 1.03% from the stock’s previous close.
Other equities research analysts also recently issued research reports about the company. Canaccord Genuity set a $47.00 target price on Advanced Accelerator Applications and gave the company a “buy” rating in a report on Thursday, July 27th. Zacks Investment Research raised Advanced Accelerator Applications from a “hold” rating to a “buy” rating and set a $91.00 target price for the company in a report on Wednesday, November 1st. Jefferies Group LLC reissued a “buy” rating and issued a $60.00 target price (up previously from $50.00) on shares of Advanced Accelerator Applications in a report on Friday, September 1st. BidaskClub raised Advanced Accelerator Applications from a “hold” rating to a “buy” rating in a report on Thursday, August 3rd. Finally, JMP Securities downgraded Advanced Accelerator Applications from an “outperform” rating to a “market perform” rating in a report on Monday, October 30th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $69.80.
Advanced Accelerator Applications (NASDAQ:AAAP) traded down $0.04 during trading hours on Monday, reaching $81.16. 296,974 shares of the company were exchanged, compared to its average volume of 256,454. Advanced Accelerator Applications has a 1 year low of $23.50 and a 1 year high of $81.50.
Advanced Accelerator Applications (NASDAQ:AAAP) last posted its quarterly earnings data on Thursday, August 31st. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). Advanced Accelerator Applications had a negative net margin of 43.93% and a negative return on equity of 20.49%. The firm had revenue of $40.14 million during the quarter, compared to analysts’ expectations of $36.74 million. equities analysts anticipate that Advanced Accelerator Applications will post -0.75 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: This story was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was stolen and republished in violation of U.S. & international copyright legislation. The legal version of this story can be read at https://www.americanbankingnews.com/2017/11/20/j-p-morgan-chase-co-downgrades-advanced-accelerator-applications-s-a-aaap-to-neutral.html.
A number of institutional investors have recently added to or reduced their stakes in the business. Belpointe Asset Management LLC acquired a new stake in Advanced Accelerator Applications in the third quarter valued at $587,000. California Public Employees Retirement System acquired a new position in shares of Advanced Accelerator Applications during the 3rd quarter worth $554,000. Cubist Systematic Strategies LLC acquired a new position in shares of Advanced Accelerator Applications during the 3rd quarter worth $1,064,000. Pentwater Capital Management LP acquired a new position in shares of Advanced Accelerator Applications during the 3rd quarter worth $4,192,000. Finally, Jane Street Group LLC acquired a new position in shares of Advanced Accelerator Applications during the 3rd quarter worth $451,000. 37.99% of the stock is owned by institutional investors.
Advanced Accelerator Applications Company Profile
Advanced Accelerator Applications SA is a radiopharmaceutical company. The Company develops, produces and commercializes molecular nuclear medicine (MNM), diagnostic and therapeutic products. MNM uses trace amounts of radioactive compounds to create functional images of organs and lesions and to treat diseases, such as cancer.
Receive News & Ratings for Advanced Accelerator Applications S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanced Accelerator Applications S.A. and related companies with MarketBeat.com's FREE daily email newsletter.